Chronic peptide-based GIP receptor inhibition exhibits modest glucose metabolic changes in mice when administered either alone or combined with GLP-1 agonism

Combinatorial gut hormone therapy is one of the more promising strategies for identifying improved treatments for metabolic disease. Many approaches combine the established benefits of glucagon-like peptide-1 (GLP-1) agonism with one or more additional molecules with the aim of improving metabolic o...

Descripción completa

Detalles Bibliográficos
Autores principales: West, Jason A., Tsakmaki, Anastasia, Ghosh, Soumitra S., Parkes, David G., Grønlund, Rikke V., Pedersen, Philip J., Maggs, David, Rajagopalan, Harith, Bewick, Gavin A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011784/
https://www.ncbi.nlm.nih.gov/pubmed/33788878
http://dx.doi.org/10.1371/journal.pone.0249239

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011784/
https://www.ncbi.nlm.nih.gov/pubmed/33788878
http://dx.doi.org/10.1371/journal.pone.0249239

Ejemplares similares